Imatinib and ruxolitinib association: first experience in two patients.
作者信息
Iurlo Alessandra, Gianelli Umberto, Rapezzi Davide, Cattaneo Daniele, Fermo Elisa, Binda Francesca, Santambrogio Elisa, Bucelli Cristina, Cortelezzi Agostino
机构信息
Oncohematology Unit of the Elderly, Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy Hematopathology Service, Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy Division of Hematology, Santa Croce e Carle Hospital, Cuneo, Italy Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Italy
Hematopathology Service, Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, and University of Milan Medical School, Milan, Italy.
出版信息
Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.
Abstract
摘要
相似文献
1
Imatinib and ruxolitinib association: first experience in two patients.伊马替尼与芦可替尼联合应用：两例患者的首次经验
Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.
2
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.甲磺酸伊马替尼（格列卫）：一种治疗慢性粒细胞白血病及其他恶性肿瘤的新疗法。
Drugs Today (Barc). 2002 Sep;38(9):601-13. doi: 10.1358/dot.2002.38.9.696536.
3
A patient of chronic myelogenous leukemia developing painful rash on feet.一名慢性粒细胞白血病患者足部出现疼痛性皮疹。
J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489.
4
Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.硬腭色素沉着与伊马替尼治疗慢性髓性白血病相关，该患者原癌基因c-KIT存在基因变异。
Leuk Lymphoma. 2013 Jan;54(1):186-8. doi: 10.3109/10428194.2012.702904. Epub 2012 Aug 14.
5
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.青春期接受伊马替尼治疗的慢性髓性白血病儿童的骨代谢、生长速率及青春期发育
Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14.
6
[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].[慢性骨髓增殖性疾病的病理生理学、诊断与治疗：讨论]
Nihon Naika Gakkai Zasshi. 2007 Jul 10;96(7):1434-55. doi: 10.2169/naika.96.1434.
7
Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.由急性髓系白血病演变而来的慢性髓系白血病：对甲磺酸伊马替尼的反应及良好预后。
Leuk Lymphoma. 2013 Jan;54(1):195-7. doi: 10.3109/10428194.2012.692788. Epub 2012 Jun 13.
8
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.在伊马替尼治疗慢性骨髓增殖性疾病期间发生的骨髓纤维化，该疾病同时存在BCR-ABL易位和JAK2V617F突变。
Blood. 2007 May 1;109(9):4106-7. doi: 10.1182/blood-2006-12-061135.
9
Management of the new patient with CML in chronic phase.慢性期新慢性髓性白血病患者的管理。
Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0.
10
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.接受甲磺酸伊马替尼治疗的慢性髓性白血病患者的色素沉着变化。
Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.
引用本文的文献
1
Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.酪氨酸激酶抑制剂与芦可替尼联合治疗 Jak2 阳性骨髓纤维化和 Bcr-Abl 阳性慢性粒细胞白血病并存的情况
Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025023. doi: 10.4084/MJHID.2025.023. eCollection 2025.
2
Insights from a rare myeloproliferative neoplasm with coexisting fusion gene, and mutations treated with nilotinib and ruxolitinib.一例伴有共存融合基因和突变的罕见骨髓增殖性肿瘤经尼罗替尼和芦可替尼治疗的病例分析
Clin Case Rep. 2023 Jan 23;11(1):e6801. doi: 10.1002/ccr3.6801. eCollection 2023 Jan.
3
Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?对于同时患有骨髓纤维化和慢性粒细胞白血病（CML）的患者，异基因移植是一种选择吗？
Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021062. doi: 10.4084/MJHID.2021.062. eCollection 2021.
4
Cytokines frequently implicated in myeloproliferative neoplasms.细胞因子经常与骨髓增殖性肿瘤有关。
Cytokine X. 2019 Mar 27;1(1):100005. doi: 10.1016/j.cytox.2019.100005. eCollection 2019 Mar.
5
Busy signal: platelet-derived growth factor activation in myelofibrosis.忙碌信号：骨髓纤维化中血小板衍生生长因子的激活
Haematologica. 2020 Aug;105(8):1988-1990. doi: 10.3324/haematol.2020.253708.
6
Coexistence of -positive chronic myeloid leukemia and -mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.携带 BCR-ABL 阳性的慢性粒细胞白血病与 JAK2 突变的骨髓纤维化共存，经达沙替尼和芦可替尼成功治疗。 （注：原文中存在信息缺失，推测完整内容可能是这样，仅供参考，具体需结合完整原文准确翻译。这里按照推测补充了BCR-ABL和JAK2，以使译文完整通顺。）
Blood Res. 2019 Mar;54(1):77-79. doi: 10.5045/br.2019.54.1.77. Epub 2019 Mar 21.
7
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.一例发生于原发性血小板增多症治疗患者的慢性粒细胞白血病病例。
Am J Case Rep. 2019 Jan 3;20:10-14. doi: 10.12659/AJCR.911854.
8
Treatment of Myelofibrosis: Old and New Strategies.骨髓纤维化的治疗：新旧策略
Clin Med Insights Blood Disord. 2017 Mar 8;10:1179545X17695233. doi: 10.1177/1179545X17695233. eCollection 2017.
9
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis.芦可替尼可改善系统性肥大细胞增多症患者的症状和生活质量。
Biomark Res. 2016 Feb 5;4:2. doi: 10.1186/s40364-016-0056-5. eCollection 2016.
10
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.用芦可替尼和达沙替尼治疗的JAK2 V617F阳性真性红细胞增多症与BCR-ABL阳性慢性粒细胞白血病并存病例
Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77.
本文引用的文献
1
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.芦可替尼与第二代酪氨酸激酶抑制剂的选择性强强协同作用，克服慢性髓性白血病中骨髓基质相关的药物耐药性。
Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15.
2
Advances in myelofibrosis: a clinical case approach.骨髓纤维化的进展：临床病例分析。
Haematologica. 2013 Oct;98(10):1499-509. doi: 10.3324/haematol.2013.086348.
3
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.接受芦可替尼治疗的 JAK1/JAK2 抑制剂治疗患者的骨髓纤维化缓解。
Haematologica. 2013 Dec;98(12):1872-6. doi: 10.3324/haematol.2013.095109. Epub 2013 Sep 20.
4
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.3 期 COMFORT 研究中安慰剂和最佳可用疗法治疗骨髓纤维化的比较。
Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2.
5
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.芦可替尼：治疗骨髓纤维化患者的一种有效且选择性的 Janus 激酶 1 和 2 抑制剂。临床医生的最新资讯。
Ther Adv Hematol. 2012 Dec;3(6):341-54. doi: 10.1177/2040620712459746.
6
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.芦可替尼治疗对 COMFORT-I 研究中骨髓纤维化相关症状和其他患者报告结局的影响：一项随机、双盲、安慰剂对照试验。
J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19.
7
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.芦可替尼与最佳可用疗法治疗骨髓纤维化的 JAK 抑制作用比较。
N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556.
8
Long-term outcome of treatment with ruxolitinib in myelofibrosis.芦可替尼治疗骨髓纤维化的长期疗效
N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555.
9
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
10
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.基于骨髓纤维化研究与治疗国际工作组的一项研究的原发性骨髓纤维化新预后评分系统。
Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.
Zotero 插件